Evidence map›Paper›PMID 24995146›Full record

ReviewScientifica2014

XB130-A Novel Adaptor Protein: Gene, Function, and Roles in Tumorigenesis.

Xiao-Hui Bai, Hae-Ra Cho, Serisha Moodley, Mingyao Liu

Open access · goldAbstract readReview
In one paragraph

Review in Scientifica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Chinese medical journal · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xiao-Hui BaiLatner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, 101 College Street, Toronto, ON, Canada M5G 1L7.
Hae-Ra ChoLatner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, 101 College Street, Toronto, ON, Canada M5G 1L7 ; Department of Physiology, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON, Canada M5S 1A8.ORCID 0000-0001-8109-5870
Serisha MoodleyLatner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, 101 College Street, Toronto, ON, Canada M5G 1L7 ; Institute of Medical Science, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON, Canada M5S 1A8.ORCID 0000-0001-6413-9704
Mingyao LiuLatner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, 101 College Street, Toronto, ON, Canada M5G 1L7 ; Department of Physiology, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON, Canada M5S 1A8 ; Institute of Medical Science, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON, Canada M5S 1A8 ; Department of Surgery, Faculty of Medicine, University of Toronto, 149 College Street, Toronto, ON, Canada M5T 1P5.ORCID 0000-0002-9188-8417
University Health Network · CAUniversity of New Brunswick · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several adaptor proteins have previously been shown to play an important role in the promotion of tumourigenesis. XB130 (AFAP1L2) is an adaptor protein involved in many cellular functions, such as cell survival, cell proliferation, migration, and gene and miRNA expression. XB130's functional domains and motifs enable its interaction with a multitude of proteins involved in several different signaling pathways. As a tyrosine kinase substrate, tyrosine phosphorylated XB130 associates with the p85 α regulatory subunit of phosphoinositol-3-kinase (PI3K) and subsequently affects Akt activity and its downstream signalling. Tumourigenesis studies show that downregulation of XB130 expression by RNAi inhibits tumor growth in mouse xenograft models. Furthermore, XB130 affects tumor oncogenicity by regulating the expression of specific tumour suppressing miRNAs. The expression level and pattern of XB130 has been studied in various human tumors, such as thyroid, esophageal, and gastric cancers, as well as, soft tissue tumors. Studies show the significant effects of XB130 in tumourigenesis and suggest its potential as a diagnostic biomarker and therapeutic target for cancer treatments.

Identifiers

PMID24995146
PMCPMC4068053
OpenAlexW2172176682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.